Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 908-914

  Scheithauer, W ^a   Kornek, G ^a   Marczell, A ^a   Salem, G ^a   Karner, J ^a   Kovats, E ^a   Burger, D ^a   Greiner, R ^a   Pidlich, J ^a   Schneeweiss, B ^a   Raderer, M ^a   Rosen, H ^a   Depisch, D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUMFOLINAT; FLUOROURACIL; FOLINIC ACID; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNE DEFICIENCY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TREATMENT OUTCOME;

EID: 0031059138     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.908     Document Type: Article

References (34)

1. Mayer RJ: Chemotherapy for metastatic colorectal cancer. Cancer 70:1414-1424, 1992
2. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752-755, 1993
3. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
4. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
5. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1990
6. Doroshow JH: Biochemical modulation of fluoropyrimidines: Is there an optimal (6R,S) leucovorin dose and schedule? J Natl Cancer Inst 88:393-395, 1996
7. Keyomarsi K, Moran RG: Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263:14402-14409, 1988
8. White JC, Bailey BD, Goldman ID: Lack of stereospecifity at carbon 6 of methyl-tetrahydrofolate transport in Ehrlich ascites tumor cells. Carrier-mediated transport of both stereoisomers. J Biol Chem 253:242-245, 1978
9. Sirotnak FM, Chello PL, Moccio DM, et al: Stereospecifity at carbon 6 of formyltetra-hydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28:2993-2997, 1979
10. Sato JK, Moran RG: Interaction of methotrexate and citrovorum factor at folyl-polyglutamate synthetase. Proc Am Assoc Cancer Res 25:312, 1984 (abstr)
11. Romanini A, Lin JT, Niedzwiecki D, et al: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51:789-793, 1991
12. Newman EM, Straw JA, Doroshow JH: Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 49:5755-5760, 1989
13. Bertrand R, Jolivet J: Lack of interference by the unnatural isomer of 5-formyltetra-hydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 15:1175-1177, 1989
14. Schüller J, Czejka M, Piertrzak C, et al: Serum and tissue levels of 1-folinic acid (FA) after iv bolus of either racemic (d,1) FA or pure 1-enantiomer (1-FA). Proc Am Soc Clin Oncol 15:175, 1996 (abstr)
15. Zittoun J: Pharmacokinetics and in vitro studies of 1-leucovorin. Comparison with the d and d,1-leucovorin. Ann Oncol 4:1-5, 1993 (suppl 2)
16. Machover D, Grison X, Goldschmidt E, et al: Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: A phase I-II study. J Natl Cancer Inst 84:321-327, 1992
17. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
18. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
19. Jäger E, Heike M, Bernhard H, et al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. J Clin Oncol 14:2274-2279, 1996
20. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
21. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
22. World Health Organization: Handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
23. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Peto R, Peto J: Asymptotically efficient invariant procedures. J R Stat Soc A 135:185-206, 1972
25. Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 63:1036-1044, 1989
26. Nobile MT, Sanguineti O, Barzacchi MC, et al: Twenty-four hours weekly infusion of 5-fluorouracil (5-FU) and oral 6S-leucovorin (L-LV) in advanced colorectal cancer. Proc Am Soc Clin Oncol 12:227, 1993 (abstr)
27. Zaniboni A, Meriggi, F, Arcangeli G, et al: L-folinic acid and 5-fluorouracil in the treatment of advanced breast cancer: A phase II study. Ann Oncol 4:41-43, 1993 (suppl 2)
28. Dimery I, Shirinian M, Goepfert H, et al: Phase II clinical and pharmacology study of cisplatin (CDDP), 5-fluorouracil (5-FU), and 1-leucovorin (1-LV) induction therapy of locally advanced resectable squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 12:279, 1993 (abstr)
29. Goldberg RM, O'Connell MJ, Wieand HS, et al: A prospective randomized trial of intensive course 5-FU combined with a) the 1-isomer of intravenous leucovorin, b) oral (d,1) leucovorin or c) intravenous (d,1) leucovorin for the treatment of advanced colorectal cancer: A North Central Cancer Treatment Group trial. Proc Am Soc Clin Oncol 15:207, 1996 (abstr)
30. Valone FH, Gandara DR, Luce JA, et al: Phase I trial of a 5-day infusion of 1-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol 32:215-220, 1993
31. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
32. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
33. Erlichmann C, Fine S, Kerr I, et al: A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. Am J Clin Oncol 19:26-31, 1966
34. Herrmann R: Thymidylate synthase inhibition, a dead end? Eur J Cancer 31A:1919-1920, 1995